Logo image of GRAY

GRAYBUG VISION INC (GRAY) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GRAY - US38942Q1031 - Common Stock

5.5 USD
-0.67 (-10.8%)
Last: 3/20/2023, 8:12:53 PM
6.51 USD
+1.01 (+18.36%)
After Hours: 3/20/2023, 8:12:53 PM
Fundamental Rating

2

Taking everything into account, GRAY scores 2 out of 10 in our fundamental rating. GRAY was compared to 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for GRAY as it has an excellent financial health rating, but there are worries on the profitability. GRAY has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • GRAY had negative earnings in the past year.
  • In the past year GRAY has reported a negative cash flow from operations.
GRAY Yearly Net Income VS EBIT VS OCF VS FCFGRAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

  • The profitability ratios for GRAY are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRAY Yearly ROA, ROE, ROICGRAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

  • GRAY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRAY Yearly Profit, Operating, Gross MarginsGRAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022

More info and screens

7

2. Health

2.1 Basic Checks

  • The number of shares outstanding for GRAY has been increased compared to 1 year ago.
  • GRAY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GRAY Yearly Shares OutstandingGRAY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 5M 10M 15M 20M
GRAY Yearly Total Debt VS Total AssetsGRAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • GRAY has an Altman-Z score of -8.80. This is a bad value and indicates that GRAY is not financially healthy and even has some risk of bankruptcy.
  • GRAY has a Altman-Z score of -8.80. This is in the lower half of the industry: GRAY underperforms 76.92% of its industry peers.
  • GRAY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.8
ROIC/WACCN/A
WACCN/A
GRAY Yearly LT Debt VS Equity VS FCFGRAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • GRAY has a Current Ratio of 10.72. This indicates that GRAY is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of GRAY (10.72) is better than 83.71% of its industry peers.
  • GRAY has a Quick Ratio of 10.72. This indicates that GRAY is financially healthy and has no problem in meeting its short term obligations.
  • GRAY has a Quick ratio of 10.72. This is amongst the best in the industry. GRAY outperforms 83.71% of its industry peers.
Industry RankSector Rank
Current Ratio 10.72
Quick Ratio 10.72
GRAY Yearly Current Assets VS Current LiabilitesGRAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 1.70% over the past year.
EPS 1Y (TTM)1.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, GRAY will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.89% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.14%
EPS Next 2Y13.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRAY Yearly Revenue VS EstimatesGRAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 100M 200M 300M
GRAY Yearly EPS VS EstimatesGRAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • GRAY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRAY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRAY Price Earnings VS Forward Price EarningsGRAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRAY Per share dataGRAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 -100 200 -200 300

4.3 Compensation for Growth

  • GRAY's earnings are expected to grow with 13.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.89%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for GRAY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRAYBUG VISION INC

NASDAQ:GRAY (3/20/2023, 8:12:53 PM)

After market: 6.51 +1.01 (+18.36%)

5.5

-0.67 (-10.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-09
Earnings (Next)05-08
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners146.19%
Ins Owner Change0%
Market Cap617.26K
Revenue(TTM)N/A
Net Income(TTM)-35.60M
Analysts43.33
Price Target42.84 (678.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.5%
Min EPS beat(2)-2.5%
Max EPS beat(2)-2.5%
EPS beat(4)1
Avg EPS beat(4)-6.08%
Min EPS beat(4)-23.06%
Max EPS beat(4)7.33%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1100%
PT rev (3m)1100%
EPS NQ rev (1m)-58.7%
EPS NQ rev (3m)-58.7%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.02
P/tB 0.02
EV/EBITDA N/A
EPS(TTM)-1.66
EYN/A
EPS(NY)-1.69
Fwd EYN/A
FCF(TTM)-206.6
FCFYN/A
OCF(TTM)-203.86
OCFYN/A
SpS0
BVpS320.51
TBVpS320.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 91.12%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.72
Quick Ratio 10.72
Altman-Z -8.8
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)146.72%
Cap/Depr(5y)290.92%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.81%
EPS Next Y5.14%
EPS Next 2Y13.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.37%
OCF growth 3YN/A
OCF growth 5YN/A

GRAYBUG VISION INC / GRAY FAQ

Can you provide the ChartMill fundamental rating for GRAYBUG VISION INC?

ChartMill assigns a fundamental rating of 3 / 10 to GRAY.


Can you provide the valuation status for GRAYBUG VISION INC?

ChartMill assigns a valuation rating of 3 / 10 to GRAYBUG VISION INC (GRAY). This can be considered as Overvalued.


How profitable is GRAYBUG VISION INC (GRAY) stock?

GRAYBUG VISION INC (GRAY) has a profitability rating of 1 / 10.


Can you provide the financial health for GRAY stock?

The financial health rating of GRAYBUG VISION INC (GRAY) is 5 / 10.